Evidence map›Paper›PMID 35356507›Full record

ArticlePathology oncology research : POR2022

Correlations Between the Expression of Stromal Cell Activation Related Biomarkers, L-NGFR, Phospho-ERK1-2 and CXCL12, and Primary Myelofibrosis Progression.

Tamas Szekely, Tibor Krenacs, Mate Elod Maros, Csaba Bodor, Viktoria Daubner, Annamaria Csizmadia, Brigitta Vrabely, Botond Timar

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathology oncology research : POR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. The Duality of Collagens in Metastases of Solid Tumors.International journal of molecular sciences · 2025
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Tamas SzekelyFirst Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Tibor KrenacsFirst Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Mate Elod MarosFirst Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Csaba BodorFirst Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Viktoria DaubnerFirst Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Annamaria CsizmadiaFirst Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Brigitta VrabelyDepartment of Pathology, Sandor Peterfy Street Hospital and Clinic, Budapest, Hungary.
Botond TimarFirst Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Semmelweis University · HUHUN-REN Institute of Experimental Medicine · HUPéterfy Sándor Utcai Kórház-Rendelőintézet és Baleseti Központ · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In myelofibrosis, pathologically enhanced extracellular matrix production due to aberrant cytokine signalling and

Indexed as

Mesenchymal Stem CellsPrimary MyelofibrosisBiomarkersChemokine CXCL12Endothelial CellsHumansNerve Tissue ProteinsReceptors, Nerve Growth FactorStromal CellsBiomarkersChemokine CXCL12CXCL12 protein, humanNerve Tissue ProteinsNGFR protein, humanReceptors, Nerve Growth Factor-connexin 43 channels-CXCL12-L-NGFR/CD271-phospho-ERK1-2primary myelofibrosis progression-stromal cell activation

Identifiers

PMID35356507
PMCPMC8958997
OpenAlexW4220846435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.